PapersTrialsTopicsCompoundsCountriesStakeholdersPeopleCoursesEvents
Browse all papers

Latest papers

Long-term efficacy of psilocybin with adjunct psychotherapy in treatment-resistant depressionPsilocybin · Treatment-resistant depressionDrug-drug interactions between psychiatric medications and MDMA or psilocybinMDMA & psilocybin · SafetyAn international mega-analysis of psychedelic drug effects on brain circuit functionCross-compound · NeuroimagingEsketamine in treatment-resistant depression with and without comorbid borderline personalityEsketamine · Treatment-resistant depression

Featured

Road to Access

Science, regulation, and economics on the path to patient access.

01Evidence02Approval03Reimbursement04Delivery05Access—Big Picture
Start the journey
ResultsCompare outcome data across trials and publications.Research SnapshotOne-page overview of trials, participants, papers, and research networks.Clinical GuidelinesTrial-anchored manuals and protocol guidance with competency mapping.Research recapsMonthly evidence summaries with key takeaways.Map of researchLandscape view of trials, compounds, and outcomes.NewsletterWeekly or daily updates on trials, publications, analysis, and more.Research GroupsWorldwide map of psychedelic research centres by region.Research NetworkInteractive co-authorship map of psychedelic researchers.Top papersFind needles in the haystack of psychedelic research per topic.
AskBeta
Pricing
Back to journals
Academic JournalOpen Access

CME Journal of Neurology and Neuroscience

1 Papers Indexed in Blossom

Data updated June 29, 2026

Research Footprint

CME Journal of Neurology and Neuroscience has 1 tracked paper indexed in Blossom (2026) from 1 author, most often covering Ibogaine, across Health Economics & Reimbursement.

Published Papers

Open Accessmeta

Cost-Effectiveness of Medically Monitored Ibogaine for Opioid Use Disorder in Tennessee: A State-Specific Semi-Markov Analysis

This cost-effectiveness modelling study (n=106,000) of Tennessee adults with opioid use disorder found that adding a medically monitored ibogaine pathway to standard care was less costly and produced more quality-adjusted life-years and better survival over ten years. Cost savings depended on programme cost and durability assumptions, though health gains held across conservative scenarios.

Published
June 8, 2026
Journal
CME Journal of Neurology and Neuroscience

Quick Facts

Papers Indexed
1
h-Index
18
Open Access
Yes
Publisher
CME
Country
United States
Website
Visit

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.